New lawyer silences bad-boy ex-pharma CEO Martin Shkreli
February 3, 2016 By Tom Hays Associated Press
Former Turing Pharmaceuticals CEO Martin Shkreli, center, listens as his lawyer Benjamin Brafman, left, speaks to reporters as they leave court in Brooklyn on Wednesday. Shkreli, who has become the poster child of pharmaceutical-industry greed after hiking the price of an anti-infection drug by more than 5,000 percent, is scheduled to appear at a congressional hearing on Thursday. AP Photo/Seth Wenig
Bad-boy ex-pharmaceutical company CEO and prolific social media user Martin Shkreli has been muzzled.
A new lawyer in a federal securities fraud case against Shkreli told reporters outside court on Wednesday that his client would stop speaking out in his own defense until the charges are resolved.
“We want to try this case in the courtroom and not in the media,” defense attorney Benjamin Brafman said with a silent Shkreli at his side following a pretrial hearing in Brooklyn.
Shkeli, 32, gained notoriety last year after a drug company he founded, Turing Pharmaceuticals, spent $55 million for the U.S. rights to sell a life-saving medicine called Daraprim and promptly raised the price from $13.50 to $750 per pill.
The Brooklyn Daily Eagle and brooklyneagle.com cover Brooklyn 24/7 online and five days a week in print with the motto, “All Brooklyn All the Time.” With a history dating back to 1841, the Eagle is New York City’s only daily devoted exclusively to Brooklyn.